Jingjing Jiang
Vice President, Cancer Pharmacology, Translational Research Revolution Medicines
Seminars
Wednesday 17th September 2025
Targeting Oncogenic RAS with Tri-Complex RAS(ON) Inhibitors
9:00 am
- RAS(ON) inhibitors selectively target the active GTP-bound form of oncogenic RAS and lead to deep and durable responses in preclinical models of RAS-driven tumors
- RAS(ON) mutant- and multi-selective inhibition has demonstrated anti-tumor activity in RAS addicted PDAC and NSCLC
- Potential combination strategies to forestall/address emerging resistance mechanisms to RAS(ON) inhibition are being explored
Wednesday 17th September 2025
Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficacy
1:00 pm
- Â Uncovering the current status and unmet medical needs for patients with RAS-driven cancers, what cancers need more improved response rates?
- What genomic features predict poor response and outcomes for RAS-targeting therapies?
- How do you successfully overcome or delay resistance to RAS-targeting therapies?
Tuesday 16th September 2025
Panel Discussion: Identifying the Right Combination for Different Cancers by Tailoring RAS Inhibitors for Tumor-Specific Reponses
11:30 am
- Overcoming the complexity of tumor biology and multiple signaling pathways to select the optimal combination approach for different cancer types
- How can patient-specific genetic profiles and tumor microenvironment data inform the design of more effective combination therapies?
- How do RAS inhibitors alter the tumor microenvironment and improve response to current standard of care cancer treatments?
